A Spike-Based MRNA Vaccine Encapsulated in Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine Containing Lipid Nanoparticles Induced Potent B- and T-Cell Responses Associated with Protection Against SARS-CoV-2 Infection and COVID-19-like...

Overview

Journal Vaccines (Basel)

Date 2025 Jan 24

PMID 39852826

Authors

Afshana Quadiri

Swayam Prakash

Latifa Zayou

Nisha Rajeswari Dhanushkodi

Amruth Chilukuri

Gemma Ryan

Kelly Wang

Hawa Vahed

Aziz A Chentoufi

Lbachir BenMohamed

Affiliations

Soon will be listed here.

Abstract

Background: Nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNPs) have emerged as a promising vaccine strategy, especially for COVID-19. While the LNPs protect mRNA from degradation and efficiently deliver the mRNA to antigen-presenting cells, the effect of lipid composition on the immunogenicity and protective efficacy of mRNA/LNP vaccines is not well characterized. Studies on using the mRNA/LNP platform for vaccines have largely focused on the nucleic acid cargo with less attention paid to the LNP vehicle. Whether the composition and biophysical properties of LNPs impact vaccine performance remains to be fully elucidated.

Methods: In the present study, we used SARS-CoV-2 Spike-mRNA as a prototype vaccine to study the effect of four different LNPs with various lipid compositions.

Results: We demonstrate that when the same Spike-mRNA was delivered in the LNP4 formulation based on phospholipid 1,2-dioleoyl-sn-glycero-3-Phosphoethanolamine, it outperformed other LNPs (LNP1, LNP2, and LNP3) that are based on different lipids. Compared to the other three LNPs, LNP4 (i) enhanced the phenotypic and functional maturation of dendritic cells; (ii) induced strong T-cell responses; (iii) increased the secretion of proinflammatory cytokines and pro-follicular T helper (Tfh) cell cytokines; (iv) induced higher neutralization IgG titers; and (v) provided better protection against SARS-CoV-2 infection and COVID-19-like symptoms in the hamster model. Furthermore, we compared LNP-4 with the commercially available LNPs and found it to provide better T-cell immunity against COVID-19 in hamsters.

Conclusion: This study suggests mRNA vaccines encapsulated in Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine containing LNPs induced Potent B- and T cell immunity. The mechanisms by which Phospholipid 1,2-Dioleoyl-sn-Glycero-3-PhosphoEthanolamine-based LNPs may activate protective B and T cells are discussed.

References

Hakiem O, Rizvi S, Ramirez C, Tan M . Euo is a developmental regulator that represses late genes and activates midcycle genes in . mBio. 2023; 14(5):e0046523. PMC: 10653925. DOI: 10.1128/mbio.00465-23. View

Dangi T, Palacio N, Sanchez S, Park M, Class J, Visvabharathy L . Cross-protective immunity following coronavirus vaccination and coronavirus infection. J Clin Invest. 2021; 131(24). PMC: 8670840. DOI: 10.1172/JCI151969. View

Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Tran J . Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa. J Immunol. 2023; 211(1):118-129. PMC: 10330291. DOI: 10.4049/jimmunol.2300093. View

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias C . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021; 27(4):620-621. DOI: 10.1038/s41591-021-01270-4. View

Roces C, Lou G, Jain N, Abraham S, Thomas A, Halbert G . Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics. Pharmaceutics. 2020; 12(11). PMC: 7697682. DOI: 10.3390/pharmaceutics12111095. View

Hassett K, Higgins J, Woods A, Levy B, Xia Y, Hsiao C . Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021; 335:237-246. DOI: 10.1016/j.jconrel.2021.05.021. View

Rouzine I, Rozhnova G . Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies. Commun Med (Lond). 2023; 3(1):86. PMC: 10279745. DOI: 10.1038/s43856-023-00320-x. View

Bailey A, Cullis P . Membrane fusion with cationic liposomes: effects of target membrane lipid composition. Biochemistry. 1997; 36(7):1628-34. DOI: 10.1021/bi961173x. View

Saadati F, Cammarone S, Ciufolini M . A Route to Lipid ALC-0315: a Key Component of a COVID-19 mRNA Vaccine. Chemistry. 2022; 28(48):e202200906. PMC: 9348069. DOI: 10.1002/chem.202200906. View

10.

Quadiri A, Kori L, Singh S, Anvikar A . Antibody Responses Against MSP3 Protein During Natural Malaria Infection in Individuals Living in Malaria-Endemic Regions of India. Proc Natl Acad Sci India Sect B Biol Sci. 2022; 92(3):613-619. PMC: 8985746. DOI: 10.1007/s40011-021-01330-2. View

11.

Kiaie S, Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F . Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnology. 2022; 20(1):276. PMC: 9194786. DOI: 10.1186/s12951-022-01478-7. View

12.

Tenchov R, Bird R, Curtze A, Zhou Q . Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021; 15(11):16982-17015. DOI: 10.1021/acsnano.1c04996. View

13.

Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q . A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Cent Sci. 2021; 7(4):512-533. PMC: 8029445. DOI: 10.1021/acscentsci.1c00120. View

14.

Ubaid S, Kashif M, Laiq Y, Nayak A, Kumar V, Singh V . Targeting HIF-1α in sickle cell disease and cancer: unraveling therapeutic opportunities and risks. Expert Opin Ther Targets. 2024; 28(5):357-373. DOI: 10.1080/14728222.2024.2367640. View

15.

Wilson B, Geetha K . Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J Drug Deliv Sci Technol. 2022; 74:103553. PMC: 9238147. DOI: 10.1016/j.jddst.2022.103553. View

16.

Prakash S, Dhanushkodi N, Zayou L, Ibraim I, Quadiri A, Coulon P . Cross-protection induced by highly conserved human B, CD4, and CD8 T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern. Front Immunol. 2024; 15:1328905. PMC: 10839970. DOI: 10.3389/fimmu.2024.1328905. View

17.

Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Shaik A . Antiviral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models. J Immunol. 2024; 212(4):576-585. DOI: 10.4049/jimmunol.2300392. View

18.

Hald Albertsen C, Kulkarni J, Witzigmann D, Lind M, Petersson K, Simonsen J . The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022; 188:114416. PMC: 9250827. DOI: 10.1016/j.addr.2022.114416. View

19.

Pardi N, Muramatsu H, Weissman D, Kariko K . In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol. 2013; 969:29-42. DOI: 10.1007/978-1-62703-260-5_2. View

20.

Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078-1094. PMC: 8353930. DOI: 10.1038/s41578-021-00358-0. View